Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Am Heart Assoc ; 13(13): e033558, 2024 Jul 02.
Article in English | MEDLINE | ID: mdl-38904226

ABSTRACT

BACKGROUND: The incidental use of statins during radiation therapy has been associated with a reduced long-term risk of developing atherosclerotic cardiovascular disease. We examined whether irradiation causes chronic vascular injury and whether short-term administration of statins during and after irradiation is sufficient to prevent chronic injury compared with long-term administration. METHODS AND RESULTS: C57Bl/6 mice were pretreated with pravastatin for 72 hours and then exposed to 12 Gy X-ray head-and-neck irradiation. Pravastatin was then administered either for an additional 24 hours or for 1 year. Carotid arteries were tested for vascular reactivity, altered gene expression, and collagen deposition 1 year after irradiation. Treatment with pravastatin for 24 hours after irradiation reduced the loss of endothelium-dependent vasorelaxation and protected against enhanced vasoconstriction. Expression of markers associated with inflammation (NFκB p65 [phospho-nuclear factor kappa B p65] and TNF-α [tumor necrosis factor alpha]) and with oxidative stress (NADPH oxidases 2 and 4) were lowered and subunits of the voltage and Ca2+ activated K+ BK channel (potassium calcium-activated channel subfamily M alpha 1 and potassium calcium-activated channel subfamily M regulatory beta subunit 1) in the carotid artery were modulated. Treatment with pravastatin for 1 year after irradiation completely reversed irradiation-induced changes. CONCLUSIONS: Short-term administration of pravastatin is sufficient to reduce chronic vascular injury at 1 year after irradiation. Long-term administration eliminates the effects of irradiation. These findings suggest that a prospective treatment strategy involving statins could be effective in patients undergoing radiation therapy. The optimal duration of treatment in humans has yet to be determined.


Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors , Mice, Inbred C57BL , Oxidative Stress , Pravastatin , Animals , Pravastatin/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Oxidative Stress/drug effects , Oxidative Stress/radiation effects , Time Factors , Vasoconstriction/drug effects , Vasoconstriction/radiation effects , Vasodilation/drug effects , Vasodilation/radiation effects , Male , NADPH Oxidase 2/metabolism , NADPH Oxidase 2/genetics , Tumor Necrosis Factor-alpha/metabolism , Transcription Factor RelA/metabolism , NADPH Oxidases/metabolism , Mice , Radiation Injuries, Experimental/prevention & control , Radiation Injuries, Experimental/metabolism , Radiation Injuries, Experimental/drug therapy , Drug Administration Schedule , Carotid Arteries/radiation effects , Carotid Arteries/drug effects , Chronic Disease , Disease Models, Animal , NADPH Oxidase 4
SELECTION OF CITATIONS
SEARCH DETAIL